Filed under: Investing
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Arrowhead Research , a clinical-stage biopharmaceutical company focused on developing RNAi-based therapeutics, tumbled as much as 11% after the company announced a new clinical candidate.
So what: According to the company's midday press release, Arrowhead's next clinical candidate will be ARC-AAT, an RNAi therapeutic targeted at liver disease associated with Alpha-1 antitrypsin deficiency, or AATD. In the words of Arrowhead's president and CEO Christopher Anzalone, "ARC-AAT is designed to inhibit the production of mutant AAT protein in the liver and in preclinical studies it has shown high levels of knockdown with long duration of action." In primate studies, Arrowhead noted an AAT reduction of greater than 80% at the six-week mark. Initial studies will examine adult patients with signs of liver injury, but further clinical investigations may be undertaken for children.
Now what: Today's move lower looks more like profit taking tied to the fact that shares surged around 35% during the prior four days, rather than a genuine reaction to the release of a new clinical candidate. Obviously, there are plenty of questions that will surround ARC-AAT, and Arrowhead investors can now expect research and development costs to increase as a new clinical study is added to the pipeline. However, Cincinnati Children's hospital is estimating that as many as one in 3,000 people may have AATD, and many people currently undiagnosed; therefore, if ARC-AAT is successful in human studies, it could prove to have quite the bounty of opportunity.
Arrowhead Research may have worlds of potential, but even it could struggle to keep pace with this top stock.
Give us five minutes, and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer handpicks one stock with outstanding potential. But it's not just any run-of-the-mill company; it's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year, his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252%, and 1,303% during the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
The article Why Arrowhead Research Corp. Shares Swooned originally appeared on Fool.com.Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.